Baidu
map

Mov Disord: 帕金森:脑脊液中的哪些蛋白,影响突触核蛋白的稳态

2021-08-08 Freeman MedSci原创

与神经递质分泌、突触可塑性和内溶酶体自噬有关的CSF蛋白,可能作为PD和DLB中与α-突触核苷酸蛋白稳态有关的生物标志物。

在大多数α-突触核蛋白病患者中,如帕金森病(PD)和路易体痴呆(DLB),其共同的病理特征是α-突触核蛋白的异常构象的聚集。

随后,在遗传研究以及细胞和动物模型中发现了几个与α-synuclein蛋白稳态有关的分子途径。这些途径包括自噬功能受损,例如内溶酶体功能障碍、泛素-蛋白酶体系统、线粒体稳态和突触可塑性。

尽管有这些明确的证据表明涉及的途径,但缺乏有效的生物标志物,这些标志物在人类生物流体中是明确的疾病和/或途径特异性的。

最近的一项研究,使用固相萃取法结合平行反应监测质谱法(solid-phase extraction combined with parallel reaction monitoring mass spectrometry ),对3组帕金森病患者、阿尔茨海默病(AD)患者和健康对照组的脑脊液(CSF)中与自噬性内溶酶体和泛素蛋白酶体功能相关的肽/蛋白质谱进行了有针对性的探索。

有趣的是,PD患者的溶酶体相关膜糖蛋白1和2(LAMP1和LAMP2)、 cathepsin F (CTSF)、神经节苷脂GM2激活剂(GM2A)、AP-2复合体亚单位β(AP2B1)和泛素的CSF蛋白水平低于AD患者、前驱AD患者和健康对照者。

随着技术的进步,最近的一个无偏见的定量蛋白质组学(unbiased quantitative proteomics approach )方法,使用液相色谱-串联质谱,报告了与神经递质分泌有关的蛋白质(颗粒蛋白家族)的CSF水平下降,以及与健康对照组相比,散发性PD患者的粘连结(adherens junctions )。

具体来说,PD患者的神经分泌蛋白VGF、secretogranin 2(SCG2)、secretogranin和secretogranin、chromogranin-A(CHGA)和chromogranin-B以及cadherins的CSF蛋白水平都较低。

根据这一证据,德国图宾根大学的Stefanie Lerche等人,探究了与α-synuclein蛋白稳态途径相关的CSF蛋白谱,在2个大型单中心的α-synuclein病症队列中(共385名PD患者和67名DLB患者),并将其与健康对照组相比。

由于溶酶体伴侣介导的自噬功能受损,代表了PD的一个关键机制,他们特别纳入了葡萄糖苷酸酶(GBA)基因有变异的PD患者(385人中的80人)和DLB患者(67人中的17人)。

鉴于DLB患者与PD相比,以及GBA变体患者与野生型患者相比,α-突触蛋白的病理变化加快,临床轨迹明显,主要假设是,这些患者群体的情况将更加不同。

他们发现:
(1)与健康对照组相比,PD和DLB患者中与神经递质分泌、突触可塑性和内溶酶体自噬有关的蛋白质含量较低。

(2) 这些模式在DLB患者中比在PD患者中更明显,在这两个实体中,GBA变体状态更突出。

(3) 这些蛋白的CSF水平与总α-突触核蛋白的CSF水平呈正相关,即:蛋白稳态低的那些蛋白,含量更低,且与总α-突触核蛋白的低水平有关。

(4) 这些发现可被纵向证实。与蛋白酶谱正常的PD患者相比,CSF蛋白酶谱低的PD患者,在纵向上,显示出较低的α-synuclein水平。

这个研究的重要意义在于发现了:与神经递质分泌、突触可塑性和内溶酶体自噬有关的CSF蛋白,可能作为PD和DLB中与α-突触核苷酸蛋白稳态有关的生物标志物。


原文出处:
Lerche S, Sjödin S, Brinkmalm A, et al. CSF Protein Level of Neurotransmitter Secretion, Synaptic Plasticity, and Autophagy in PD and DLB. Mov Disord. Published online June 28, 2021:mds.28704. doi:10.1002/mds.28704

 
 
 
 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1646770, encodeId=8fab1646e70cd, content=<a href='/topic/show?id=4478e5315e1' target=_blank style='color:#2F92EE;'>#稳态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75315, encryptionId=4478e5315e1, topicName=稳态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ebc23344390, createdName=changfy, createdTime=Tue Mar 01 11:20:36 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986099, encodeId=e888198609935, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sat Apr 02 22:20:36 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013684, encodeId=977820136842a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Aug 29 23:20:36 CST 2021, time=2021-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478814, encodeId=823a14e8814b3, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Mon Aug 09 20:20:36 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784452, encodeId=27b61e84452f7, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Wed Sep 01 12:20:36 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005960, encodeId=c56c1005960d3, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2de65566989, createdName=ms4000000798104243, createdTime=Sun Aug 08 09:36:03 CST 2021, time=2021-08-08, status=1, ipAttribution=)]
    2022-03-01 changfy
  2. [GetPortalCommentsPageByObjectIdResponse(id=1646770, encodeId=8fab1646e70cd, content=<a href='/topic/show?id=4478e5315e1' target=_blank style='color:#2F92EE;'>#稳态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75315, encryptionId=4478e5315e1, topicName=稳态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ebc23344390, createdName=changfy, createdTime=Tue Mar 01 11:20:36 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986099, encodeId=e888198609935, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sat Apr 02 22:20:36 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013684, encodeId=977820136842a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Aug 29 23:20:36 CST 2021, time=2021-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478814, encodeId=823a14e8814b3, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Mon Aug 09 20:20:36 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784452, encodeId=27b61e84452f7, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Wed Sep 01 12:20:36 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005960, encodeId=c56c1005960d3, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2de65566989, createdName=ms4000000798104243, createdTime=Sun Aug 08 09:36:03 CST 2021, time=2021-08-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1646770, encodeId=8fab1646e70cd, content=<a href='/topic/show?id=4478e5315e1' target=_blank style='color:#2F92EE;'>#稳态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75315, encryptionId=4478e5315e1, topicName=稳态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ebc23344390, createdName=changfy, createdTime=Tue Mar 01 11:20:36 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986099, encodeId=e888198609935, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sat Apr 02 22:20:36 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013684, encodeId=977820136842a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Aug 29 23:20:36 CST 2021, time=2021-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478814, encodeId=823a14e8814b3, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Mon Aug 09 20:20:36 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784452, encodeId=27b61e84452f7, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Wed Sep 01 12:20:36 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005960, encodeId=c56c1005960d3, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2de65566989, createdName=ms4000000798104243, createdTime=Sun Aug 08 09:36:03 CST 2021, time=2021-08-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1646770, encodeId=8fab1646e70cd, content=<a href='/topic/show?id=4478e5315e1' target=_blank style='color:#2F92EE;'>#稳态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75315, encryptionId=4478e5315e1, topicName=稳态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ebc23344390, createdName=changfy, createdTime=Tue Mar 01 11:20:36 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986099, encodeId=e888198609935, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sat Apr 02 22:20:36 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013684, encodeId=977820136842a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Aug 29 23:20:36 CST 2021, time=2021-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478814, encodeId=823a14e8814b3, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Mon Aug 09 20:20:36 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784452, encodeId=27b61e84452f7, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Wed Sep 01 12:20:36 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005960, encodeId=c56c1005960d3, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2de65566989, createdName=ms4000000798104243, createdTime=Sun Aug 08 09:36:03 CST 2021, time=2021-08-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1646770, encodeId=8fab1646e70cd, content=<a href='/topic/show?id=4478e5315e1' target=_blank style='color:#2F92EE;'>#稳态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75315, encryptionId=4478e5315e1, topicName=稳态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ebc23344390, createdName=changfy, createdTime=Tue Mar 01 11:20:36 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986099, encodeId=e888198609935, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sat Apr 02 22:20:36 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013684, encodeId=977820136842a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Aug 29 23:20:36 CST 2021, time=2021-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478814, encodeId=823a14e8814b3, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Mon Aug 09 20:20:36 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784452, encodeId=27b61e84452f7, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Wed Sep 01 12:20:36 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005960, encodeId=c56c1005960d3, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2de65566989, createdName=ms4000000798104243, createdTime=Sun Aug 08 09:36:03 CST 2021, time=2021-08-08, status=1, ipAttribution=)]
    2021-09-01 cmsvly
  6. [GetPortalCommentsPageByObjectIdResponse(id=1646770, encodeId=8fab1646e70cd, content=<a href='/topic/show?id=4478e5315e1' target=_blank style='color:#2F92EE;'>#稳态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75315, encryptionId=4478e5315e1, topicName=稳态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ebc23344390, createdName=changfy, createdTime=Tue Mar 01 11:20:36 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986099, encodeId=e888198609935, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sat Apr 02 22:20:36 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013684, encodeId=977820136842a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Aug 29 23:20:36 CST 2021, time=2021-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478814, encodeId=823a14e8814b3, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Mon Aug 09 20:20:36 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784452, encodeId=27b61e84452f7, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Wed Sep 01 12:20:36 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005960, encodeId=c56c1005960d3, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2de65566989, createdName=ms4000000798104243, createdTime=Sun Aug 08 09:36:03 CST 2021, time=2021-08-08, status=1, ipAttribution=)]
    2021-08-08 ms4000000798104243

    有意思

    0

相关资讯

Mov Disord:血液中的细胞外囊泡,可有效诊断帕金森

德国波恩大学研究团队发现血浆胞外囊泡中的α-synuclein浓度,可作为PD的潜在诊断生物标志物。

Mov Disord-新型标记物: 鞘氨醇-1-磷酸酯可预测帕金森的病情进展

新型标记物: 鞘氨醇-1-磷酸酯可预测帕金森的病情进展

Mov Disord:帕金森患者,外周血的免疫特征如何?

与HCs相比,PD患者的外周免疫谱发生改变,NLR较高。

Mov Disord:双侧卵巢切除术后,女性更容易患帕金森病

双侧卵巢切除术后,女性更容易患帕金森病。

Mov Disord:早期帕金森患者,脑脊液的神经递质如何变化?

早期帕金森患者,脑脊液的神经递质如何变化?

Mov Disord:新量表,助力帕金森患者的胃肠道紊乱状态评估

帕金森病胃肠功能紊乱量表是一种新型的疾病特异性自我报告工具,并可定量评估帕金森病患者胃肠功能紊乱特征的存在和严重程度,具有很强的可靠性和有效性。

拓展阅读

好文推荐 | 脑深部电刺激术对帕金森病患者眼球运动影响的研究进展

DBS对眼球运动的影响可能为我们提供关键线索,以了解DBS的作用机制,以及受刺激的基底神经节部分的生理功能。本文对这一领域的研究进展进行综述。

帕金森病的睡眠问题:从RBD到不宁腿!

正确认识PD睡眠障碍的类型、病因及治疗方案,将有助于PD睡眠障碍的有效治疗。

JNNP:长期太极拳训练对帕金森病的影响:3.5年随访队列研究

太极拳训练对帕金森病具有长期有益作用,可改善运动和非运动症状,减少并发症。

论著|帕金森病心血管系统自主神经功能与排尿症状相关性研究

本研究旨在探究PD患者自主神经功能改变中心血管系统与排尿症状之间的相关性,揭示可能的共同病理生理机制,进而为PD患者的全面评估和个体化治疗提供理论依据。

病例报告|帕金森病合并重症肌无力1例

PD合并MG较为罕见,结合文献复习阐述其可能的共病机制及治疗策略,以期提高临床医生对此合并症的全面认识与诊治能力。关键词 

2024 NICE 介入程序指南:磁共振成像(MRI)引导的聚焦超声丘脑底核切开术用于治疗帕金森病 [IPG797]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2024-12-18

2024 NICE 介入程序指南:磁共振成像引导的聚焦超声丘脑切开术用于治疗帕金森病中重度震颤 [IPG796]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2024-12-18

Baidu
map
Baidu
map
Baidu
map